Breakout Ventures has announced the launch of its third fund, reinforcing its commitment to early-stage, science-driven companies. The new fund will continue the firm's focus on founders using artificial intelligence to solve complex challenges in biology and chemistry. This capital deployment aims to accelerate the commercialization of groundbreaking scientific innovations.
A Legacy of Successful Investments
The firm builds upon a history of strong performance, having already returned capital to investors from its inaugural fund. Standout investments include Cytovale, which developed the first FDA-cleared AI-powered rapid sepsis diagnostic. Another notable company is Twelve, a manufacturer creating sustainable aviation fuel directly from air.
Momentum continued with Fund II, which was announced in 2021 and has seen significant success. A prime example is the acquisition of portfolio company Surf Bio by Halozyme in a deal valued at up to $400 million. This exit delivered a substantial return for Breakout Ventures as the lead investor.
Fueling Innovation in Health and Technology
The firm's portfolio demonstrates a focus on companies at the forefront of their fields. Noetik, for instance, secured a landmark partnership with GSK worth $50 million upfront to build foundational AI models for human biology. This collaboration positions Noetik within the pharmaceutical industry's evolving AI infrastructure.
Another portfolio company, Phantom Neuro, is making strides in human-machine interfaces without requiring brain surgery. The company received FDA Breakthrough Device Designation for its technology enabling real-time control of prosthetic limbs. This highlights the firm's support for ventures navigating complex regulatory pathways to clinical reality.
In the sustainability sector, ZymoChem is pioneering fossil-free chemistry to produce high-performance polymers at scale. The company is reprogramming industrial processes to create materials that replace petrochemicals, validated by a partnership with Lululemon. This proves sustainable solutions can compete on cost, performance, and environmental impact.
The Vision for Fund III
Managing Partner Lindy Fishburne stated that AI is fundamentally altering the economics of scientific development. She noted the convergence of AI with vast biological and chemical datasets creates unprecedented speed and efficiency. The new fund is designed to capitalize on these changing return profiles by backing scientific founders.
Capital from Fund III is already being actively deployed into new seed-stage companies. Initial investments include Reach Industries, which is building a visual intelligence layer for regulated environments. Two other stealth companies, one a university spinout and another founded by industry veterans, are also part of the cohort.
Strategic Partnership and Firm Growth
The value of Breakout's partnership extends beyond financial backing, a point echoed by portfolio founders. Ron Alfa, CEO of Noetik, praised the firm for its conviction and strategic insights that sharpened their business model. He also highlighted how the firm's curated network provided a significant boost to their momentum.
Coinciding with the new fund, Breakout Ventures has promoted investor Nima Ronaghi, PhD, to Partner. This promotion recognizes his contributions to the firm's performance and signals a continued investment in its internal expertise. The move strengthens the firm's leadership as it embarks on its most ambitious chapter.
With the launch of Fund III, Breakout Ventures solidifies its role as a crucial partner for founders turning scientific breakthroughs into world-changing companies. Managing Partner Julia Moore emphasized that this work requires more than capital, citing the need for believers with deep expertise and conviction. The firm is poised to continue translating complex science into scalable enterprises that will shape our future.